Skip to content
AnalystLens

Omega Healthcare Investors 8-K Report, Corporate Update (Jun 6, 2025)

Reports
Other Events·Exhibits & Filings
Filing Date
Filed June 6, 2025
Period End
June 6, 2025
Security
OHI
In the record · 2016–202610-K1210-Q348-K126

OHI filed 12 annual reports (10-K), 34 quarterly reports (10-Q) and 126 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · May ’17May ’17
  2. Material agreement8-K · Oct ’20Oct ’20
  3. Leadership change8-K · Jan ’23Jan ’23
  4. Leadership change8-K · Oct ’26Oct ’26

Summary

Summary of the 8-K filed June 6, 2025. Cited figures are marked; the original filing is the authoritative source.

Omega Healthcare Investors, Inc. filed a Form 8-K on June 6, 2025 under Item 8.01 (Other Events) to report that it had filed a prospectus supplement for its existing Dividend Reinvestment and Common Stock Purchase Plan (the "Plan") under its automatic shelf registration statement on Form S-3ASR (No. 333-277916), originally filed March 14, 2024.

The DRCSPP Prospectus Supplement continues the offering of the Company's common stock, par value $0.10a per share, under the Plan, which was previously covered by a prospectus supplement filed March 14, 2024. The supplement registers an aggregate of 22,447,054 shares of Common Stock for issuance under the Registration Statement. The Plan allows existing stockholders and interested new investors to purchase Common Stock and reinvest all or a percentage of their cash dividends in additional shares.

The filing's exhibits consist of legal opinions from Shapiro Sher Guinot & Sandler, P.A. (Exhibit 5.1) and Bryan Cave Leighton Paisner LLP (Exhibit 8.1), along with related consents and the cover page interactive data file. The filing is administrative in nature and does not report financial results, dividends, or changes in the Company's financial condition.

The 8-K states that it does not constitute an offer to sell or a solicitation of an offer to buy any securities. It was signed by Robert O. Stephenson, Chief Financial Officer, Treasurer and Assistant Secretary.

Key Highlights

  1. Filed a prospectus supplement on June 6, 2025 for the Dividend Reinvestment and Common Stock Purchase Plan (DRCSPP) under Form S-3ASR No. 333-277916.
  2. Continues the offering of common stock, par value $0.10 per share, under the Plan, previously covered by a March 14, 2024 prospectus supplement.
  3. Registers an aggregate of 22,447,054 shares of Common Stock for issuance under the Registration Statement.
  4. The Plan lets existing stockholders and new investors buy common stock and reinvest all or part of their cash dividends.
  5. Exhibits include legal opinions from Shapiro Sher Guinot & Sandler, P.A. (Exhibit 5.1) and Bryan Cave Leighton Paisner LLP (Exhibit 8.1), with related consents.
  6. The filing reports no financial results, dividend declarations, or financial statement figures.

Frequently Asked Questions

  1. What did Omega Healthcare Investors file on June 6, 2025?

    The Company filed a prospectus supplement for its Dividend Reinvestment and Common Stock Purchase Plan under its automatic shelf registration statement on Form S-3ASR (No. 333-277916), and reported it on this Form 8-K under Item 8.01 (Other Events).

  2. How many shares are registered under the new prospectus supplement?

    The prospectus supplement registers an aggregate of 22,447,054 shares of Common Stock for issuance under the Registration Statement.

  3. What is the purpose of the Dividend Reinvestment and Common Stock Purchase Plan?

    The Plan is designed to give existing stockholders and interested new investors a way to buy Common Stock and invest all or a percentage of their cash dividends in additional shares.

  4. Does this filing report new financial results or dividend changes?

    No. The filing addresses only the continuation and registration of shares under the Plan and does not report financial results, dividend declarations, or changes in financial condition.

  5. Who provided the legal opinions attached to the filing?

    Shapiro Sher Guinot & Sandler, P.A. provided the opinion in Exhibit 5.1, and Bryan Cave Leighton Paisner LLP provided the opinion in Exhibit 8.1 relating to the DRCSPP Prospectus Supplement.